title: Endothelial injury markers with high-dose intravenous iron therapy in renal failure.
abstract: Endothelial injury is prevalent in patients with chronic renal failure (CRF) and may be exacerbated by commonly used intravenous (IV) iron therapy. The effects of high-dose IV iron sucrose treatment (200 mg daily in 250 mL of 0.9% saline, administered over 1 hour, median treatment duration 5 days) on circulating endothelium and/or tissue injury markers such as hepatocyte growth factor, thrombomodulin, von Willebrand factor, and C-reactive protein levels were studied. The markers were determined in 24 anemic (mean hemoglobin 9.48 g/dL) pre-dialysis (median creatinine clearance 21.5 mL/min) patients with CRF and defined absolute and/or functional iron deficiency. The measurements were performed before iron administration and 24 hours after the last infusion. All the markers remained unchanged following the IV iron therapy (all p < 0.172); no thrombotic or other adverse effects were observed. In conclusion, the above high-dose IV iron sucrose supplementation does not cause evident endothelial or other tissue injury in patients with CRF, and is clinically safe.
authors.affiliation: Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bialystok, Poland. jborawski@post.pl
authors.forename: Jacek
authors.initials: J
authors.lastname: Borawski
authors.forename: Joanna
authors.initials: J
authors.lastname: Gozdzikiewicz
authors.forename: Pawel
authors.initials: P
authors.lastname: Abramowicz
authors.forename: Beata
authors.initials: B
authors.lastname: Naumnik
authors.forename: Michal
authors.initials: M
authors.lastname: Mysliwiec
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy*; D018180:Thrombomodulin / Q000097:blood; D013927:Thrombosis / Q000139:chemically induced; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D015415:Biomarkers; D005290:Ferric Compounds; D018180:Thrombomodulin; D014841:von Willebrand Factor; D017228:Hepatocyte Growth Factor; D007501:Iron; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid